The intratumoral CDN treatment also increased the response rate to T-cell receptor activation by checkpoint-modulating antibodies to CTLA-4, PD-1, 4-1BB, and OX40, resulting in significant increases in median survival time in animal models of melanoma (B16-F10 and YUMM1.7), breast adenocarcinoma (E0771), prostate cancer (TRAMP-C2), head and neck squamous cell cancers (SCCFVII) [72,73], HER-2+ breast tumours [76], glioblastoma multiforme [77], glioma [70], neuroblastoma [75], and 4T1 breast tumour [72,74,78,79,80,81]. The gene discussed is ERBB2; the disease is breast neoplasm.